Home
Resources
Product Analysis
Acknowledgements
About
Home
References
Biotech components
Biotech components
Bacteria
Products 1 to 10 of 53
Modify Display Properties
Biotech components
Business models
Country of production
Country of distribution
Intended consumer
Date added
Date last modified
Known funding amount
Funding types
Industry
Market status
Organization
Organization type(s)
Product categories
Production process
Source
Trading symbol
Value chain stage
Sort: Title (A-Z)
Date added (oldest-newest)
Date added (newest-oldest)
Date modified (oldest-newest)
Date modified (newest-oldest)
Title (A-Z)
Title (Z-A)
Organization (A-Z)
Organization (Z-A)
100% n-butanol (Cyanobacteria)
by
Phytonix
Biotech components:
Bacteria
Business models:
B2B
Country of production:
USA
Country of distribution:
USA
+
Sweden
+
Canada
Intended consumer:
Commercial
Date added:
2018/08/30 11:49 (5 years ago)
Date last modified:
2018/08/30 11:49 (5 years ago)
Known funding amount:
N/A
Funding types:
Venture Capital
Industry:
Industrial
Market status:
Under Development
Organization type(s):
Private Company
Product categories:
Chemical
Production process:
Closed Production
Source:
NASEM Database
Trading symbol:
N/A
Value chain stage:
Input
ActoBiotics: AG013 (Oral Mucositis)
by
Actobio Therapeutics
Biotech components:
Bacteria
Business models:
B2C
Country of production:
N/A
Country of distribution:
N/A
Intended consumer:
N/A
Date added:
2019/09/12 15:12 (4 years ago)
Date last modified:
2019/09/12 15:12 (4 years ago)
Known funding amount:
N/A
Funding types:
Government
+
Shareholder Investment
Industry:
Medical
Market status:
Under Development
Organization type(s):
Private Company
Product categories:
Personal Care (Topical)
+
Medicine
Production process:
N/A
Source:
Web search
Trading symbol:
XON
(NASDAQ)
Value chain stage:
Finished Product
ActoBiotics: AG017 (Celiac Disease)
by
Actobio Therapeutics
Biotech components:
Bacteria
Business models:
B2C
Country of production:
N/A
Country of distribution:
N/A
Intended consumer:
N/A
Date added:
2019/09/12 15:12 (4 years ago)
Date last modified:
2019/09/16 16:28 (4 years ago)
Known funding amount:
N/A
Funding types:
Private Funding
+
Shareholder Investment
Industry:
Health
+
Medical
Market status:
Early Stage Concept
Organization type(s):
Private Company
Product categories:
Personal Care (Ingested)
Production process:
N/A
Source:
Web search
Trading symbol:
XON
(NASDAQ)
Value chain stage:
Finished Product
ActoBiotics: AG018 (Rhinosinusitus)
by
Actobio Therapeutics
Biotech components:
Bacteria
Business models:
B2C
Country of production:
N/A
Country of distribution:
N/A
Intended consumer:
N/A
Date added:
2019/09/12 15:12 (4 years ago)
Date last modified:
2019/09/12 15:12 (4 years ago)
Known funding amount:
N/A
Funding types:
Private Funding
+
Shareholder Investment
Industry:
Medical
Market status:
Under Development
Organization type(s):
Private Company
Product categories:
Personal Care (Topical)
Production process:
N/A
Source:
Web search
Trading symbol:
XON
(NASDAQ)
Value chain stage:
Finished Product
ActoBiotics: AG019 (Type 1 Diabetes)
by
Actobio Therapeutics
Biotech components:
Bacteria
Business models:
B2C
Country of production:
N/A
Country of distribution:
N/A
Intended consumer:
N/A
Date added:
2019/09/12 15:12 (4 years ago)
Date last modified:
2019/09/12 15:12 (4 years ago)
Known funding amount:
N/A
Funding types:
Private Funding
+
Shareholder Investment
Industry:
Medical
Market status:
Under Development
Organization type(s):
Private Company
Product categories:
Medical Treatment
+
Medicine
Production process:
N/A
Source:
Web search
Trading symbol:
XON
(NASDAQ)
Value chain stage:
Finished Product
ActoBiotics: AG020 (Inflammatory Bowel Disease)
by
Actiobio Therapeutics
Biotech components:
Bacteria
Business models:
B2C
Country of production:
N/A
Country of distribution:
N/A
Intended consumer:
N/A
Date added:
2019/09/12 15:12 (4 years ago)
Date last modified:
2019/09/12 15:12 (4 years ago)
Known funding amount:
N/A
Funding types:
Private Funding
+
Shareholder Investment
Industry:
Medical
Market status:
Early Stage Concept
Organization type(s):
Private Company
Product categories:
Personal Care (Topical)
Production process:
N/A
Source:
Web search
Trading symbol:
XON
(NASDAQ)
Value chain stage:
Finished Product
Agri-Pure Fatty Acids
by
Cargill
Biotech components:
Bacteria
Business models:
B2B
Country of production:
USA
Country of distribution:
N/A
Intended consumer:
Commercial
Date added:
2018/08/30 11:49 (5 years ago)
Date last modified:
2018/10/01 10:00 (5 years ago)
Known funding amount:
N/A
Funding types:
Private Funding
Industry:
Industrial
Market status:
On the market
Organization type(s):
Private Company
Product categories:
Chemical
Production process:
Closed Production
Source:
SynBio Database
Trading symbol:
N/A
Value chain stage:
Input
Antibiotic - EV-035
by
Emergent Biosolutions, Inc.
Biotech components:
Bacteria
Business models:
B2C
Country of production:
USA
Country of distribution:
USA
+
Switzerland
Intended consumer:
Government
Date added:
2018/08/30 11:49 (5 years ago)
Date last modified:
2018/08/30 11:49 (5 years ago)
Known funding amount:
86,000,000 CHF
Funding types:
Shareholder Investment
Industry:
Health
Market status:
Under Development
Organization type(s):
Public Company
Product categories:
Medical Treatment
Production process:
Closed Production
Source:
SynBio Database
Trading symbol:
EVE
(SWX)
Value chain stage:
Finished Product
Arsenic Whole-cell Biosensors
by
Bielefield-CeBiTech
Biotech components:
Bacteria
Business models:
B2B
+
B2C
Country of production:
Germany
Country of distribution:
Germany
Intended consumer:
Consumer
+
Commercial
+
Government
Date added:
2018/08/30 11:49 (5 years ago)
Date last modified:
2018/08/30 11:49 (5 years ago)
Known funding amount:
N/A
Funding types:
Government
Industry:
Science
Market status:
Early Stage Concept
Organization type(s):
University
+
Research Institution
Product categories:
Research
Production process:
Closed Production
Source:
SynBio Database
Trading symbol:
N/A
Value chain stage:
Finished Product
Auxin; Engineering Bacteria to Help Fight Soil Erosion
by
Imperial College
Biotech components:
Bacteria
Business models:
B2B
Country of production:
England
Country of distribution:
England
Intended consumer:
Commercial
Date added:
2018/08/30 11:49 (5 years ago)
Date last modified:
2018/08/30 11:49 (5 years ago)
Known funding amount:
N/A
Funding types:
Government
Industry:
Food & Agriculture
Market status:
Under Development
Organization type(s):
University
+
Research Institution
Product categories:
Plant
Production process:
Open Release
Source:
SynBio Database
Trading symbol:
N/A
Value chain stage:
Input
1
2
3
4
5
6
Login
or
register
to add and edit products
Future
Bioengineered
Products
Home
Resources
Product Analysis
Acknowledgements
About
